The Moses H. Cone Memorial Hospital
- Type
- Teaching hospital
- Where
- Greensboro, NC
- Medicare CCN
- 340091
- Received
- $1,621,375 in 364 records, 2019 ($124,745 general, $1,496,629 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: MOSES H CONE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 116 | $124,745 |
| 2019 | Research payment | 248 | $1,496,629 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 248 | $1,496,629 |
| Space rental or facility fees (teaching hospital only) | 63 | $50,612 |
| Gift | 29 | $33,346 |
| Grant | 5 | $26,903 |
| Education | 6 | $5,508 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 11 | $5,043 |
| Charitable Contribution | 2 | $3,331 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | CVRx, Inc. | $5,160 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $3,547 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | CVRx, Inc. | $3,100 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-12-31 | Linvatec Corporation | $1,403 | Grant | In-kind items and services | 2DHD MONITORS Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $625 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $331 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-27 | PFIZER INC. | $1,800 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-12-25 | Amgen Inc. | $1,575 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | GOULD | 2019 |
| 2019-12-25 | Amgen Inc. | $1,043 | Research payment | Cash or cash equivalent | GALACTIC-HF | 2019 | |
| 2019-12-25 | CVRx, Inc. | $5 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-12-24 | KARL STORZ Endoscopy-America | $1,020 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-12-24 | KARL STORZ Endoscopy-America | $1,020 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | KARL STORZ Endoscopy-America | $1,590 | Gift | In-kind items and services | NEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | KARL STORZ Endoscopy-America | $1,470 | Gift | In-kind items and services | NEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | KARL STORZ Endoscopy-America | $1,290 | Gift | In-kind items and services | NEEDLE HOLDER, 'KOH', MACRO Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | KARL STORZ Endoscopy-America | $1,020 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | KARL STORZ Endoscopy-America | $1,020 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | KARL STORZ Endoscopy-America | $990 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | KARL STORZ Endoscopy-America | $720 | Gift | In-kind items and services | INSERT,BOWEL GRASPER,FENESTRAT Device, LAPAROSCOPY | 2019 | |
| 2019-12-19 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-19 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-18 | CVRx, Inc. | $30,000 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-12-18 | Gilead Sciences, Inc. | $1,450 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-12-18 | Gilead Sciences, Inc. | $1,358 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2019 |
| 2019-12-17 | Merck Sharp & Dohme LLC | $4,223 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-12-16 | Becton, Dickinson and Company | $1,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-16 | Medtronic Vascular, Inc. | $667 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-12-12 | CSL Behring | $9,468 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-11 | Abbott Laboratories | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mitra Clip system Device, Vascular | 2019 | |
| 2019-12-06 | PFIZER INC. | $7,500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-12-05 | CSL Behring | $7,991 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-05 | CSL Behring | $850 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-28 | Amgen Inc. | $2,504 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | VESALIUS-CV | 2019 |
| 2019-11-20 | CVRx, Inc. | $30,000 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-11-20 | Gilead Sciences, Inc. | $691 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-11-20 | Gilead Sciences, Inc. | $491 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2019 |
| 2019-11-14 | Medtronic Vascular, Inc. | $2,959 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-11-14 | KYOWA KIRIN, INC. | $1,000 | Education | Cash or cash equivalent | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2019 | |
| 2019-11-13 | Abbott Laboratories | $6,796 | Research payment | Cash or cash equivalent | AMPLATZER PFO Occluder Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2019 |
| 2019-11-13 | Regeneron Pharmaceuticals, Inc. | $600 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Pa | 2019 |
| 2019-11-12 | Boston Scientific Corporation | $2,500 | Grant | Cash or cash equivalent | GENERAL - VASCULAR INTERVENTION Device, VASCULAR | 2019 | |
| 2019-11-08 | Merck Sharp & Dohme LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-11-08 | PORTOLA PHARMACEUTICALS, LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, HEMATOLOGY/NEUROLOGY | 2019 | |
| 2019-11-07 | CSL Behring | $23,447 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $1,050 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-06 | Regeneron Pharmaceuticals, Inc. | $943 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hype | 2019 |
| 2019-10-31 | PFIZER INC. | $1,800 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-10-30 | Abbott Laboratories | $2,232 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-10-28 | CVRx, Inc. | $18,395 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-10-25 | Varian Medical Systems, Inc. | $131,266 | Research payment | Cash or cash equivalent | Auto-Segmentation - Cone Health | 2019 | |
| 2019-10-25 | Varian Medical Systems, Inc. | $54,978 | Research payment | Cash or cash equivalent | Auto-Segmentation - Cone Health | 2019 | |
| 2019-10-25 | ConvaTec Inc. | $200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FLEXI-SEAL FMS Device, CONTINENCE AND CRITICAL CARE | 2019 | |
| 2019-10-23 | Gilead Sciences, Inc. | $1,182 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-10-23 | Gilead Sciences, Inc. | $679 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2019 |
| 2019-10-22 | PENTAX of America, Inc. | $209,107 | Research payment | In-kind items and services | Device, Gastroenterology | FDA post market Sampling and Culturing Study (FDA 522- PS15004/PS002) | 2019 |
| 2019-10-16 | Abbott Laboratories | $1,100 | Research payment | Cash or cash equivalent | Xience Device, Cardiac Arrhythmias and Heart Failure | XIENCE SHORT DAPT 28 US | 2019 |
| 2019-10-14 | Medtronic Vascular, Inc. | $3,445 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-10-10 | CSL Behring | $19,660 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-10 | CSL Behring | $850 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-09 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-02 | Amgen Inc. | $34,622 | Research payment | In-kind items and services | Repatha Biological, Cardiology | VESALIUS-CV | 2019 |
| 2019-10-02 | Regeneron Pharmaceuticals, Inc. | $2,278 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hype | 2019 |
| 2019-09-30 | PFIZER INC. | $3,600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-09-26 | Medline Industries LP | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-19 | Merck Sharp & Dohme LLC | $5,000 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-09-19 | Merck Sharp & Dohme LLC | $2,875 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-09-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-19 | Merck Sharp & Dohme LLC | $2,000 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-09-19 | Merck Sharp & Dohme LLC | $1,400 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-09-19 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-09-18 | Gilead Sciences, Inc. | $2,364 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-09-18 | Gilead Sciences, Inc. | $1,170 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2019 |
| 2019-09-17 | SANOFI PASTEUR INC. | $49,680 | Research payment | Cash or cash equivalent | YELLOW FEVER Drug | STA00011 Stamaril Yellow Fever | 2019 |
| 2019-09-17 | CSL Behring | $49,611 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-17 | CSL Behring | $2,400 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-12 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-09-09 | Medtronic Vascular, Inc. | $17,978 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-09-09 | CSL Behring | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-29 | Merck Sharp & Dohme LLC | $7,997 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-08-27 | CVRx, Inc. | $4,192 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-08-26 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-08-21 | Gilead Sciences, Inc. | $1,188 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-08-21 | Regeneron Pharmaceuticals, Inc. | $1,125 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Pa | 2019 |
| 2019-08-21 | KCI USA, Inc. | $1,000 | Education | Cash or cash equivalent | VAC VERAFLO Device, DEVICES | 2019 | |
| 2019-08-13 | CSL Behring | $22,400 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-13 | CSL Behring | $800 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-08 | Medtronic Vascular, Inc. | $168 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-08-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NINLARO Drug, Oncology | 2019 | |
| 2019-08-06 | Genentech, Inc. | $968 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2019 |
| 2019-08-06 | Merck Sharp & Dohme LLC | $850 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-07-31 | Abbott Laboratories | $1,749 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-07-30 | PFIZER INC. | $3,550 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-07-24 | Abbott Laboratories | $3,581 | Research payment | Cash or cash equivalent | AMPLATZER PFO Occluder Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2019 |
| 2019-07-23 | Merck Sharp & Dohme LLC | $1,924 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-07-17 | Gilead Sciences, Inc. | $1,679 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-07-17 | Surmodics, Inc. | $849 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-07-12 | Lundbeck LLC | $3,000 | Charitable Contribution | Cash or cash equivalent | NORTHERA Drug, NEUROLOGY | 2019 | |
| 2019-07-12 | Optinose US, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xhance Drug, Otolaryngology (Ear, Nose, Throat) | 2019 | |
| 2019-07-12 | Novartis Pharmaceuticals Corporation | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XOLAIR Biological, RESPIRATORY | 2019 | |
| 2019-07-12 | GENZYME CORPORATION | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DUPIXENT Drug, IMMUNOLOGY | 2019 | |
| 2019-07-12 | Covidien LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Auto Suture Device, Surgical Stapling | 2019 | |
| 2019-07-11 | CSL Behring | $14,813 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-07-11 | CSL Behring | $700 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-07-10 | Novartis Pharmaceuticals Corporation | $38,666 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | 2019 |
| 2019-07-08 | Amgen Inc. | $2,195 | Research payment | In-kind items and services | Repatha Biological, Cardiology | VESALIUS-CV | 2019 |
| 2019-07-07 | KARL STORZ Endoscopy-America | $1,590 | Gift | In-kind items and services | TROCAR,ONLY,BLUNT,11MM,10.5CM, Device, LAPAROSCOPY | 2019 | |
| 2019-07-07 | KARL STORZ Endoscopy-America | $900 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-07-07 | KARL STORZ Endoscopy-America | $900 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-07-07 | KARL STORZ Endoscopy-America | $900 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-07-06 | KARL STORZ Endoscopy-America | $900 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-07-06 | KARL STORZ Endoscopy-America | $900 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-07-06 | KARL STORZ Endoscopy-America | $900 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-07-06 | KARL STORZ Endoscopy-America | $900 | Gift | In-kind items and services | OUTER TUBE, CLICKLINE, W/CENTIMETER Device, LAPAROSCOPY | 2019 | |
| 2019-07-03 | CVRx, Inc. | $29 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-06-26 | Merck Sharp & Dohme LLC | $4,800 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-06-26 | ConvaTec Inc. | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AQUACEL AG Device, WOUND THERAPEUTICS | 2019 | |
| 2019-06-25 | Endo Pharmaceuticals Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NASCOBAL Drug, PRESCRIPTION SUPPLEMENT | 2019 | |
| 2019-06-21 | ABBVIE INC. | $350 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Orilissa Drug, Endocrinology | 2019 | |
| 2019-06-19 | Gilead Sciences, Inc. | $3,116 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-06-19 | Gilead Sciences, Inc. | $1,154 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2019 |
| 2019-06-19 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-19 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-06-11 | CSL Behring | $21,537 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-11 | CSL Behring | $900 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-09 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-06-09 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FASENRA Drug, Respiratory | 2019 | |
| 2019-06-06 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-06-05 | Medtronic Vascular, Inc. | $115 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-05-30 | CSL Behring | $1,200 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-29 | ACELL, INC. | $1,229 | Education | Cash or cash equivalent | 2019 | ||
| 2019-05-29 | ACELL, INC. | $1,229 | Education | Cash or cash equivalent | 2019 | ||
| 2019-05-23 | Surmodics, Inc. | $1,266 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-23 | Surmodics, Inc. | $979 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-23 | Surmodics, Inc. | $594 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-22 | Regeneron Pharmaceuticals, Inc. | $3,239 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Pa | 2019 |
| 2019-05-22 | Gilead Sciences, Inc. | $740 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-05-22 | CVRx, Inc. | $23 | Research payment | In-kind items and services | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-05-21 | E.R. Squibb & Sons, L.L.C. | $90 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Master Protocol of Phase II Studies of Nivolumab in Advanced NSCLC Nivolumab as Maintenance after Induction Chemothera | 2019 |
| 2019-05-20 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-20 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-17 | W. L. Gore & Associates, Inc. | $6,750 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-05-17 | E.R. Squibb & Sons, L.L.C. | $1,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase IIIbIV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer W | 2019 |
| 2019-05-16 | Merck Sharp & Dohme LLC | $2,500 | Research payment | Cash or cash equivalent | MK-0859 Drug, CARDIOVASCULAR | HPS 3 , TIMI 55 REVEAL Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, ran | 2019 |
| 2019-05-15 | Abbott Laboratories | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mitra Clip system Device, Vascular | 2019 | |
| 2019-05-14 | Medtronic Vascular, Inc. | $18,277 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-05-14 | BIOTRONIK INC. | $212 | Research payment | Cash or cash equivalent | Siello Device, Cardiology/Vascular Diseases | SIELLO | 2019 |
| 2019-05-14 | BIOTRONIK INC. | $175 | Research payment | Cash or cash equivalent | Siello Device, Cardiology/Vascular Diseases | SIELLO | 2019 |
| 2019-05-09 | CSL Behring | $41,012 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-09 | CSL Behring | $1,800 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-06 | Aesculap, Inc. | $2,714 | Gift | Cash or cash equivalent | 2019 | ||
| 2019-05-02 | Novartis Pharmaceuticals Corporation | $1,000 | Research payment | Cash or cash equivalent | TYKERB Drug, ONCOLOGY | A PHASE I DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LAPATINIB IN COMBINATION WITH CARBOPLATIN PACLI | 2019 |
| 2019-05-02 | Surmodics, Inc. | $849 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-02 | Surmodics, Inc. | $849 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-02 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-02 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-02 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-02 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-02 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-02 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-02 | Surmodics, Inc. | $594 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-02 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-05-01 | Abbott Laboratories | $2,214 | Research payment | Cash or cash equivalent | AMPLATZER PFO Occluder Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2019 |
| 2019-05-01 | Medline Industries LP | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-04-30 | Covidien LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BIS Device, Cerebral/Somatic Oximetry | 2019 | |
| 2019-04-29 | Novartis Pharmaceuticals Corporation | $2,630 | Research payment | Cash or cash equivalent | AFINITOR Drug, ONCOLOGY | AN OPEN LABEL PHASE II SINGLE ARM STUDY OF EVEROLIMUS IN COMBINATION WITH LETROZOLE IN THE TREATMENT OF POSTMENOPAUSAL W | 2019 |
| 2019-04-26 | Penumbra, Inc. | $750 | Education | Cash or cash equivalent | 2019 | ||
| 2019-04-26 | Genentech, Inc. | $484 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2019 |
| 2019-04-25 | Medtronic Vascular, Inc. | $35 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2019 |
| 2019-04-24 | CVRx, Inc. | $16,113 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2019 | |
| 2019-04-24 | Abbott Laboratories | $4,781 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-04-24 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-04-23 | PORTOLA PHARMACEUTICALS, LLC | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ANDEXXA Biological, HEMATOLOGY/NEUROLOGY | 2019 | |
| 2019-04-18 | Smith+Nephew, Inc. | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | REDAPT Revision Hip System Device, Recon Hips | 2019 | |
| 2019-04-18 | Astellas Pharma US Inc | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2019 | |
| 2019-04-17 | Medtronic Vascular, Inc. | $1,875 | Research payment | Cash or cash equivalent | CareLink Device, Cardiac Diagnostics and Monitoring | BlueSync | 2019 |
| 2019-04-17 | Gilead Sciences, Inc. | $1,730 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-04-17 | Gilead Sciences, Inc. | $1,181 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2019 |
| 2019-04-17 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-04-17 | PFIZER INC. | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SUTENT Drug, ONCOLOGY;RESPIRATORY | 2019 | |
| 2019-04-16 | CSL Behring | $11,279 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-04-16 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-04-16 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-04-16 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
The latest 200 records of 364.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Greensboro, NC | County Guilford County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 301,198 | 547,940 | 10,730,404 |
| Population, 2020 census P1 | 299,035 | 541,299 | 10,439,388 |
| Median age B01002 | 34.3 | 37.5 | 39.1 |
| Under 18 B01001 | 21.7% | 22.0% | 21.8% |
| 65 and over B01001 | 14.4% | 15.9% | 17.2% |
| Households B11001 | 123,984 | 219,718 | 4,282,345 |
| Foreign born B05002 | 12.7% | 11.8% | 9.1% |
| Median household income B19013 | $61,515 | $68,642 | $72,388 |
| Median family income B19113 | $80,585 | $88,156 | $90,290 |
| Per capita income B19301 | $37,531 | $39,376 | $41,385 |
| Poverty rate B17001 | 17.0% | 14.6% | 13.0% |
| Unemployment rate B23025 | 5.1% | 4.6% | 4.7% |
| Civilian labor force B23025 | 158,568 | 282,362 | 5,336,863 |
| Mean commute (minutes) B08013 | 21.7 | 22.0 | 25.1 |
| Bachelor's degree or higher B15003 | 41.0% | 39.0% | 35.7% |
| Housing units B25001 | 135,665 | 238,032 | 4,895,668 |
| Owner-occupied B25003 | 50.5% | 59.9% | 66.6% |
| Renters B25003 | 49.5% | 40.1% | 33.4% |
| Median home value B25077 | $244,800 | $259,900 | $288,900 |
| Median gross rent B25064 | $1,172 | $1,163 | $1,228 |
| White, not Hispanic B03002 | 38.1% | 46.0% | 60.0% |
| Black B03002 | 41.0% | 33.5% | 20.0% |
| Hispanic or Latino B03002 | 10.5% | 10.1% | 11.3% |
| Asian B03002 | 5.2% | 5.4% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.
Comments